Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease.

ABSTRACT:

Background

One-third of inflammatory bowel disease (IBD) patients show no response to infliximab (IFX) induction therapy, and approximately half of patients responding become unresponsive over time. Thus, identification of potential treatment response biomarkers are of great clinical significance. This study employs spectroscopy-based metabolic profiling of serum from patients with IBD treated with IFX and healthy subjects (1) to substantiate the use of spectroscopy as a semi-invasive diagnostic tool, (2) to identify potential biomarkers of treatment response and (3) to characterise the metabolic changes during management of patients with tumour necrosis factor-α inhibitors.

Methods

Successive serum samples collected during IFX induction treatment (weeks 0, 2, 6 and 14) from

SUBMITTER: Bjerrum JT 

PROVIDER: S-EPMC5641999 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature